MNOV•MediciNova said its experimental oral drug MN-001 lowered triglycerides in a 40-patient mid-stage trial, but the difference versus placebo was not statistically significant. Shares fell 25.4%.
After 24 weeks, triglycerides fell about 22% with MN-001 versus about 7% with placebo, a difference that was not statistically significant. The drug significantly increased HDL, while reductions in liver fat and body weight were not statistically significant. No drug-related serious side effects were reported, and MediciNova said a larger study is needed to further assess the drug's effectiveness.
